Short answer
Thermo Fisher Scientific (TMO) filed its Q3 2025 10-Q quarterly report on Oct 31, 2025 for the quarter ended Sep 27, 2025. Quarterly revenue was $11.1B (up 4.9% year over year) with net income of $1.6B.
Q3 2025 key financials · XBRL
- Revenue
- $11.1B
- +4.9% YoY · +2.5% QoQ
- Net income
- $1.6B
- −0.9% YoY · −0.1% QoQ
- Operating margin
- 17.4%
- EPS (diluted)
- $4.27
- +0.5% YoY · −0.2% QoQ
Source: XBRL data from the Thermo Fisher Scientific (TMO) Q3 2025 10-Q on SEC EDGAR. USD.
Thermo Fisher Scientific Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $11,122M Q3 2025, up $524M YoY from $10,598M in Q3 2024
- GAAP operating margin 17.4% Q3 2025 vs 17.3% Q3 2024; Adjusted margin 23.3% vs 22.3%
- Best segment: Life Sciences Solutions revenue $2,588M (+8.4% YoY), margin 37.4% (+2.0 pts)
- Worst segment: Analytical Instruments margin 22.6% Q3 2025 vs 24.9% Q3 2024 (-2.3 pts) despite revenue growth
- Cash & equivalents down to $1.982B from $4.009B end of 2024; Operating cash flow $4.361B YTD, Free cash flow $3.319B YTD
- Management notes near-term headwinds in China and strategic investments impacting margins; expects 2025 adjusted tax rate ~10.5%
Risk Factors
- No material changes to risk factors since 2024 10-K filing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Thermo Fisher Scientific quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.